VENOM2: When Animal Venoms Open Up New Avenues in the Fight Against Cancer

Photo: (c) Shutterstock - Craig Cordier

Animal venoms are a remarkable source of molecular diversity. The study of venoms, known as venomomics, enables the identification and characterization of the peptides and proteins that make them up. Optimized by evolution to interact rapidly and selectively with biological targets, some of these peptides could offer new opportunities to better detect, understand, or target cancer cells. 

A project supported by the SPW Research Win4SpinOff program

This is the avenue being explored by the VENOM2 project (Venom-based Exploration for Novel Oncology Molecules), which has just received Win4SpinOff funding, a measure from SPW Research designed to support the maturation of research results with a view to creating spin-off companies in Wallonia.

Targeting the most treatment-resistant cancers

VENOM2 is initially focusing on a refractory cancer for which treatment options remain limited. This choice is based in particular on the growing interest in certain biological targets involved in tumor progression and treatment resistance, which peptides derived from venoms could help to better detect, modulate, or target. 

A joint doctoral thesis between ULiège and UNamur

The project is being conducted under the joint supervision of Professors Loïc Quinton (Mass Spectrometry Laboratory, MolSys / Faculty of Sciences, ULiège) and Jean-Pierre Gillet—in the picture - (Laboratory of Molecular Cancer Biology (LBMC), NARILIS Research Institute, Faculty of Medicine, UNamur). It draws on the complementary nature of their respective areas of expertise: on the one hand, mass spectrometry, proteomics, and the detailed analysis of complex biological mixtures such as venoms; on the other hand, the study of mechanisms of cancer resistance to treatments.

The project is led by Lou Freuville, a joint PhD student at MSLab ULiège and LBMC UNamur. In this context, she benefits from the joint supervision of her two advisors to successfully carry out this project.

An approach combining analytical expertise and cancer biology

Specifically, VENOM2 will combine venom fractionation, functional screening on healthy and cancerous cell models, and advanced structural analyses to identify peptides capable of specifically targeting cancer cells or mechanisms involved in tumor progression. The approach thus combines ULiège’s analytical expertise in peptide characterization with UNamur’s expertise in biological and cellular cancer models.

The project’s originality lies in its dual potential for commercialization. Some peptides could be developed as targeting agents for molecular imaging, contributing to more precise diagnosis. Other candidates could have therapeutic potential by selectively modulating key biological pathways in oncology.

“With VENOM2, we aim to transform a biodiversity that remains largely underutilized into opportunities for precision oncology. The Win4SpinOff funding gives us the means to take significant new steps in research and the opportunity to test our ideas in the market. It embodies our commitment to developing innovative therapeutic solutions for cancers resistant to conventional treatments,” emphasize Professors Loïc Quinton and Jean-Pierre Gillet.

Toward a future Walloon spin-off

Beyond its scientific ambition, VENOM2 is part of a dynamic of technology transfer and value creation, laying the groundwork for a future spin-off company specializing in the development of peptides derived from venoms for human health, with the support of the technology transfer teams at ULiège, UNamur, and ULiège’s commercialization and investment company, Gesval. 

“This project lies at the intersection of several areas of expertise: detailed venom analysis, cancer biology, and the development of relevant cellular models. The goal is to identify peptides capable not only of recognizing certain tumor cells, but also of opening new avenues for better understanding and targeting mechanisms involved in cancers resistant to current treatments,” explains Lou Freuville. 

The project was developed with the support of technology transfer teams: Yasmina Zeroual for ULiège, Daniel Maréchal for Gesval, as well as Eléana Somville and Joël Marinozzi for UNamur.